Literature DB >> 32666594

In vitro stem cell modelling demonstrates a proof-of-concept for excess functional mutant TIMP3 as the cause of Sorsby fundus dystrophy.

Heidi Hongisto1,2, Jennifer M Dewing3, David Rg Christensen3, Jennifer Scott3, Angela J Cree3, Janika Nättinen4, Juha Määttä4, Antti Jylhä4, Ulla Aapola4, Hannu Uusitalo4,5, Kai Kaarniranta1,6, J Arjuna Ratnayaka3, Heli Skottman2, Andrew J Lotery3.   

Abstract

Sorsby fundus dystrophy (SFD) is a rare autosomal dominant disease of the macula that leads to bilateral loss of central vision and is caused by mutations in the TIMP3 gene. However, the mechanisms by which TIMP3 mutations cause SFD are poorly understood. Here, we generated human induced pluripotent stem cell-derived retinal pigmented epithelial (hiPSC-RPE) cells from three SFD patients carrying TIMP3 p.(Ser204Cys) and three non-affected controls to study disease-related structural and functional differences in the RPE. SFD-hiPSC-RPE exhibited characteristic RPE structure and physiology but showed significantly reduced transepithelial electrical resistance associated with enriched expression of cytoskeletal remodelling proteins. SFD-hiPSC-RPE exhibited basolateral accumulation of TIMP3 monomers, despite no change in TIMP3 gene expression. TIMP3 dimers were observed in both SFD and control hiPSC-RPE, suggesting that mutant TIMP3 dimerisation does not drive SFD pathology. Furthermore, mutant TIMP3 retained matrix metalloproteinase activity. Proteomic profiling showed increased expression of ECM proteins, endothelial cell interactions and angiogenesis-related pathways in SFD-hiPSC-RPE. By contrast, there were no changes in VEGF secretion. However, SFD-hiPSC-RPE secreted higher levels of monocyte chemoattractant protein 1, PDGF and angiogenin. Our findings provide a proof-of-concept that SFD patient-derived hiPSC-RPE mimic mature RPE cells and support the hypothesis that excess accumulation of mutant TIMP3, rather than an absence or deficiency of functional TIMP3, drives ECM and angiogenesis-related changes in SFD.
© 2020 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. © 2020 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Keywords:  Sorsby fundus dystrophy; human induced pluripotent stem cell; metalloproteinase inhibitor 3; retinal degeneration; retinal pigment epithelial cell

Mesh:

Substances:

Year:  2020        PMID: 32666594     DOI: 10.1002/path.5506

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  3 in total

1.  Treatment of Sorsby fundus dystrophy with anti-tumor necrosis factor-alpha medication.

Authors:  Richard F Spaide
Journal:  Eye (Lond)       Date:  2021-08-10       Impact factor: 4.456

2.  Extracellular matrix dysfunction in Sorsby patient-derived retinal pigment epithelium.

Authors:  Abbi L Engel; YeKai Wang; Thomas H Khuu; Emily Worrall; Megan A Manson; Rayne R Lim; Kaitlen Knight; Aya Yanagida; Jian Hua Qi; Aravind Ramakrishnan; Richard G Weleber; Michael L Klein; David J Wilson; Bela Anand-Apte; James B Hurley; Jianhai Du; Jennifer R Chao
Journal:  Exp Eye Res       Date:  2021-12-17       Impact factor: 3.770

Review 3.  Human pluripotent stem cells for the modelling of retinal pigment epithelium homeostasis and disease: A review.

Authors:  Jenna C Hall; Daniel Paull; Alice Pébay; Grace E Lidgerwood
Journal:  Clin Exp Ophthalmol       Date:  2022-07-11       Impact factor: 4.383

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.